{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-036499","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2026-09-14T20:46:13+00:00","discovered_at":"2026-09-14T20:47:41.261483+00:00","generated_at":"2026-09-14T20:48:01.996807+00:00","sec_items":["8.01","5.02"],"event_type":"litigation","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bio-Techne discloses merger proxy lawsuit, supplements disclosures","bullets":["Shareholder lawsuit filed Sept 9, 2026 in Minnesota court alleges proxy omitted material info; seeks to block merger vote.","Bio-Techne denies merit, voluntarily supplements proxy; says disclosures comply with law.","Supplement reveals Goldman Sachs implied present value of $58-$72/share (DCF) and $45-$74/share (multiple-based).","Also discloses no post-closing employment discussions with merger parties from July 2025 to agreement execution.","Special meeting for Merck KGaA merger vote remains scheduled for Sept 23, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-036499","json":"https://secwatch.observer/filing/0001140361-26-036499.json","markdown":"https://secwatch.observer/filing/0001140361-26-036499.md","text":"https://secwatch.observer/filing/0001140361-26-036499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000114036126036499/0001140361-26-036499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000114036126036499/ef20081960_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T20:48:01.996807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}